Department of Dermatology and Allergology, Klinikum Innenstadt Munich, Munich, Germany.
Skin Pharmacol Physiol. 2012;25(6):305-12. doi: 10.1159/000341809. Epub 2012 Aug 31.
This double-blind controlled phase II study was conducted to compare a newly developed formulation of mometasone furoate with a water content of 33% (Monovo® Cream) and with a smooth consistency versus the commercially available fatty cream of mometasone furoate (Ecural® Fettcreme) in terms of efficacy, cosmetic properties, and patients' acceptance. In 20 patients with mild to moderate atopic eczema, the preparations were tested intraindividually in a randomized mode and in two comparable lesion areas. Both preparations were equally effective and well tolerated. Due to improved cosmetic properties, the new formulation was preferred by the patients when asked for preferential use. Quality of life could be improved by treating with both preparations.
本双盲对照 II 期研究旨在比较一种新开发的含水量为 33%的糠酸莫米松制剂（Monovo® Cream）与市售糠酸莫米松脂状乳膏（Ecural® Fettcreme），评估其在疗效、美容性质和患者接受度方面的差异。在 20 例轻度至中度特应性皮炎患者中，以随机模式和两个可比皮损区域对两种制剂进行个体内测试。两种制剂均具有同等疗效且耐受性良好。由于美容性质改善，当被要求优先使用时，新配方更受患者青睐。两种制剂治疗均可改善生活质量。
